Patent · US Active

Pyrrolotriazine kinase inhibitors

US7531539B2 · kind B2 · utility

9Cited by
3References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 8, 2007
Grant dateMay 12, 2009
Priority date
Expiry dateAug 8, 2027

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit tyrosine kinase activity of such as TrkA, TrkB, TrkC, Jak2, Jak3 and CK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.